Prochlorperazine is a phenothiazine derivative first developed in the early 1950s during the expansion of antipsychotic research. It was introduced as a therapeutic agent with strong dopamine-blocking properties, initially intended for managing psychotic disorders. Over time, clinicians recognized its potent antiemetic effects, leading to its widespread use in treating severe nausea, vomiting, and vertigo. The drug became a standard option in both hospital and outpatient settings due to its versatility and reliability. Its long history of clinical use has contributed to a well-established safety and efficacy profile. Prochlorperazine also played an important role in shaping early pharmacologic approaches to psychiatric care. Today, it remains a valuable medication in various medical fields, reflecting decades of therapeutic relevance.
